Celldex Therapeutics (NASDAQ:CLDX) Now Covered by UBS Group

UBS Group started coverage on shares of Celldex Therapeutics (NASDAQ:CLDX - Free Report) in a research note issued to investors on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $44.00 target price on the biopharmaceutical company's stock.

Several other brokerages also recently weighed in on CLDX. Cantor Fitzgerald reissued an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Celldex Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $60.22.

Celldex Therapeutics Stock Performance

Shares of CLDX traded down $0.36 during trading hours on Thursday, hitting $22.70. The company had a trading volume of 460,616 shares, compared to its average volume of 918,381. Celldex Therapeutics has a 52-week low of $20.91 and a 52-week high of $53.18. The firm has a fifty day moving average price of $24.70 and a 200-day moving average price of $29.73. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -8.83 and a beta of 1.60.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV grew its position in Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 495 shares during the period. Invesco Ltd. boosted its stake in shares of Celldex Therapeutics by 2.1% during the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock worth $1,064,000 after acquiring an additional 871 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 878 shares during the period. Swiss National Bank increased its stake in shares of Celldex Therapeutics by 1.2% in the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company's stock worth $2,964,000 after purchasing an additional 1,400 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company's stock worth $291,000 after purchasing an additional 1,504 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.